{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:37:11Z","timestamp":1761561431673},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:sec><jats:label \/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic> 2010; <jats:bold>32:<\/jats:bold> 448\u2013458<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Crohn\u2019s disease is a chronic condition that often presents in early adulthood.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To evaluate health care costs and costs per quality\u2010adjusted life year (QALY) for Crohn\u2019s disease.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A Markov model was developed using administrative claims data for patients aged \u2265\u200318\u2003years with \u2265\u20033\u2003years of continuous enrolment from 2000 to 2008 and \u22652 Crohn\u2019s disease claims. Disease states (remission, mild\u2013moderate, moderate\u2013severe, and severe\u2013fulminant) were defined using the American College of Gastroenterology treatment guidelines criteria. Transition probabilities were calculated from consecutive 6\u2010month periods. Costs were determined from paid claims and QALY utilities were obtained from the literature. The model assumed a 30\u2010year\u2010old patient at the time of entry into the model.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> There were 40\u2003063 patients identified, with a total of 420\u2003773 cycles [remission (197\u2003111; 46.8%), mild\u2013moderate (44\u2003024; 10.5%), moderate\u2013severe (132\u2003695; 31.5%), severe\u2010fulminant (46\u2003925; 11.2%)]. The costs\/QALY for remission, mild\u2013moderate, moderate\u2013severe, and severe\u2013fulminant disease states respectively were $2896, $8428, $11\u2003518 and $69\u2003277 for males and $2896, $8426, $22\u2003633 and $69\u2003412 for females.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Overall, health care costs for patients with Crohn\u2019s disease increased with disease severity. Although the probabilities of transitioning from other health states to the severe\u2013fulminant disease state were low, the cost\/QALY was high.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04356.x","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T06:14:09Z","timestamp":1273731249000},"page":"448-458","source":"Crossref","is-referenced-by-count":18,"title":["A claims\u2010based Markov model for Crohn\u2019s disease"],"prefix":"10.1111","volume":"32","author":[{"given":"D. C.","family":"Malone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. C.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Van Den Bos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Popp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Draaghtel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. I.","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,7,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01140.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70421-4"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03276.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.07.012"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199206000-00009"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02261.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70549-4"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01779.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04033.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03671.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780030405"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta7030"},{"key":"e_1_2_6_14_2","first-page":"15","volume-title":"Economic Appraisal of Health Technology in the European Community","author":"Drummond MF","year":"1987"},{"key":"e_1_2_6_15_2","first-page":"126","volume-title":"Methods for the Economic Evaluation of Health Programmes","author":"Drummond MF","year":"1987"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03774.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90613-6"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000171273.09757.f2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20915"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20927"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462304001084"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-0725-6"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03709.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-0673.2003.01727.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.9.1229"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000159220.70290.41"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1572-0241.2003.04010.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04356.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04356.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:28:45Z","timestamp":1698737325000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04356.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04356.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04356.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,6]]}}}